Pre-operative Stereotactic Radiosurgery for Brain Cancer

Phase-Based Progress Estimates
Allegheny General Hospital, Pittsburgh, PA
Brain Cancer+2 More
Pre-operative Stereotactic Radiosurgery - Other
All Sexes
What conditions do you have?

Study Summary

This is a research study to determine if performing stereotactic radiosurgery (SRS) prior to surgical resection of the brain metastasis (tumor) will improve local control, in other words, increase the possibility of total removal of the primary tumor without local recurrence on longterm follow up. This research study will also determine if pre-operative SRS will lower the risk of radionecrosis that is the breakdown of body tissue at the original tumor site, and the development of leptomeningeal disease.

Eligible Conditions

  • Brain Cancer
  • Brain

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 4-5 years from first subject enrolled

Year 5
Radiographic Local Control
Year 5
Year 5
Leptomeningeal disease

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Pre-Operative Stereotactic Radiosurgery (SRS)
1 of 1
Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Pre-operative Stereotactic Radiosurgery · No Placebo Group · N/A

Pre-Operative Stereotactic Radiosurgery (SRS)
Experimental Group · 1 Intervention: Pre-operative Stereotactic Radiosurgery · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4-5 years from first subject enrolled
Closest Location: Allegheny General Hospital · Pittsburgh, PA
Photo of Allegheny General Hospital 1Photo of Pittsburgh 2Photo of Pittsburgh 3
2009First Recorded Clinical Trial
0 TrialsResearching Brain Cancer
256 CompletedClinical Trials

Who is running the clinical trial?

Elekta LimitedIndustry Sponsor
8 Previous Clinical Trials
6,802 Total Patients Enrolled
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)Lead Sponsor
37 Previous Clinical Trials
3,853 Total Patients Enrolled
Rodney E Wegner, MDPrincipal InvestigatorAHN Radiation Oncology
1 Previous Clinical Trials
163 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
A definitive diagnosis of solid tumor malignancy.
The maximum tumor diameter of the index lesion is less than 5 cm.
You have no prior whole brain radiotherapy (WBRT) or radiation therapy directed to the brain.
You are of childbearing potential (male or female).
Patient must be able to understand and agree to sign a written informed consent document.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.